X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Viralgen Vector Core and Elpida Therapeutics partner to manufacture adeno-associated vector serotype 9 (AAV9) based therapies, including MELPIDA, for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials.
Lead Product(s): Serotype 9 AAV Therapy
Therapeutic Area: Rare Diseases and Disorders Product Name: MELPIDA
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Elpida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 28, 2023
Details:
Axovant will have access to manufacturing resources for Axovant’s AAV-based gene therapy programs, AXO-AAV-GM1 for GM1 gangliosidosis and AXO-AAV-GM2 for GM2 gangliosidosis with sufficient capacity to support ongoing development and eventual commercialization.
Lead Product(s): AXO-AAV-GM1
Therapeutic Area: Genetic Disease Product Name: AXO-AAV-GM1
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sio Gene Therapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
